Antagonists of the orexin receptors

Expert Opinion on Therapeutic Patents

Volumn 16, Issue 5, 2006, Pages 631-646

  Cai, Jiaqiang ^a   Cooke, Fiona E ^a   Sherborne, Bradley S ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Diabetes; Feeding; Obesity; Orexin 1 receptor; Orexin 2 receptor; Orexin A; Orexin B; Sleep disorder

Indexed keywords

ACT 078573; CHLORPHENIRAMINE; CIMETIDINE; G PROTEIN COUPLED RECEPTOR; OREXIN 1 RECEPTOR; OREXIN 2 RECEPTOR; OREXIN A; OREXIN A [15-33]; OREXIN B; OREXIN B [10-28]; OREXIN B [6-28]; OREXIN B [6-28][11 ALANINE 15 DEXTRO LEUCINE]; OREXIN B [6-28][11 PROLINE]; OREXIN B [6-28][27 ALANINE]; PEPTIDE DERIVATIVE; RECEPTOR BLOCKING AGENT; SB 334867 A; SB 674042; UNCLASSIFIED DRUG;

ANTINOCICEPTION; BINDING AFFINITY; CLINICAL TRIAL; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; HIGH THROUGHPUT SCREENING; HUMAN; NEUROPATHIC PAIN; NONHUMAN; NONREM SLEEP; OBESITY; PATENT; RECEPTOR AFFINITY; REM SLEEP; REVIEW; SLEEP DISORDER; SLEEP WAKING CYCLE;

EID: 33646543700     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.16.5.631     Document Type: Review

References (74)

1. SAKURAI T, AMEMIYA A, ISHII M et al.: Orexins and orexin receptors: a family of hypothalamic neuropeptides and G-protein-coupled receptors that regulate feeding behaviour. Cell (1998) 92(4):573-585.
2. DE LECEA L, KILDUFF TS, PEYRON C et al.: The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc. Natl. Acad. Sci. USA (1998) 95:322-327.
3. VAN DEN POL AN, GAO XB, OBRIETAN K et al.: Presynaptic and postsynaptic actions and modulation of neuroendocrine neurons by a new hypothalamic peptide, hypocretin/orexin. J. Neurosci. (1998) 18:7962-7971.
4. RODGERS RJ, ISHII Y, HALFORD JC, BLUNDELL JE: Orexins and appetite regulation. Neuropeptides (2002) 36(5):303-325.
5. LANG M, SOLL RM, DURRENBERGER F et al.: Structure-activity studies of orexin A and orexin B at the human orexin 1 and orexin 2 receptors led to orexin 2 receptor selective and orexin 1 receptor preferring ligands. J. Med. Chem. (2004) 47:1153-1160.
6. SAKURAI T, MORIGUCHI T, FURUYA K et al.: Structure and function of human prepro-orexin gene. J. Biol. Chem. (1999) 274:17771-17776.
7. SAKURAI T: Orexins and orexin receptors: implication in feeding behaviour. Regul. Pept. (1999) 85(1):25-30.
8. DYER CJ, TOUCHETTE KJ, CARROLL JA et al.: Cloning of porcine preproorexin cDNA and effects of an intramuscular injection of synthetic porcine orexin B on feed intake of young pigs. Domest. Anim. Endocrinol. (1999) 16(3):145-148.
9. SMART D, JERMAN JC, BROUGH SJ et al.: Characterization of recombinant human orexin receptor pharmacology in a Chinese hamster ovary cell-line using FLIPR. Br. J. Pharmacol. (1999) 128(1):1-3.
10. DARKER JG, PORTER RA, EGGLESTON DS et al.: Structure-activity analysis of truncated orexin-A analogues at the orexin-1 receptor. Bioorg. Med. Chem. Lett. (2001) 11:737-740.
11. ASAHI S, EGASHIRA SI, MATSUDA M et al.: Development of an orexin-2 receptor selective agonist, [Ala11, D-Leu15]orexin-B. Bioorg. Med. Chem. Lett. (2003) 13(1):111-113.
12. ISHII Y, BLUNDELL JE, RODGERS RJ et al.: Satiety enhancement by selective orexin-1 receptor antagonist SB-334867: influence of test context and profile comparison with CCK-8S. Behav. Brain Res. (2005) 160:11-24.
13. CAI XJ, LIU XH, EVANS JC et al.: Orexins and feeding: special occasions or everyday occurrence? Regul. Pept. (2002) 104:1-9.
14. KIRCHGESSNER AL: Orexins in the brain-gut axis. Endocr. Rev. (2002) 23:1-15.
15. MIEDA M, YANAGISAWA M: Sleep, feeding and neuropeptides: roles of orexins and orexin receptors. Curr. Opin. Neurobiol. (2002) 12:339-345.
16. SAKURAI T: Roles of orexins in regulation of feeding and wakefulness. Neuroreport (2002) 13:987-995.
17. YAMANAKA A, BEUCKMANN CT, WILLIE JT et al.: Hypothalamic orexin neurons regulate arousal according to energy balance in mice. Neuron (2003) 38:701-713.
18. HARA J, BEUCKMANN CT, NAMBU T et al.: Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron (2001) 30:345-354.
19. HAYNES AC, JACKSON B, CHAMPMAN H et al.: A selective orexin-1 receptor antagonist reduces food consumption in male and female rats. Regul. Pept. (2000) 96:45-51.
20. EDWARDS CM, ABUSNANA S, SUNTER et al.: The effect of the orexins on food intake: comparison with neuropeptide Y, melanin-concentrating hormone and galanin. J. Endocrinol. (1999) 160:R7-R12.
21. HAYNES AC, JACKSON B, OVEREND P et al.: Effeccs of single and chronic intracerebroventricular administration of the orexins on feeding in the rat. Peptides (1999) 20:1099-1105.
22. YAMANAKA A, KUNII K, NAMBU T et al.: Orexin-induced food intake involves the neuropeptide Y pathway. Brain Res. (2000) 859:404-409.
23. YAMADA H, OKUMURA T, MOTOMURA W et al.: Inhibition of food intake by central injection of and-orexin antibody in fasted rats. Biochem. Biophys. Res. Commun. (2000) 267:527-531.
24. THORPE AJ, KOTZ CM: Orexin A in the nucleus accumbens stimulates feeding and locomotor activity. Brain Res. (2005) 1050:156-162.
25. HAGAN JJ, LESLIE RA, PATEL S et al.: Orexin A activates locus coeruleus cell firing and increases arousal in the rat. Proc. Natl. Acad. Sci. USA (1999) 96:10911-10916.
26. PIPER DC, UPTON N, SMITH MI et al.: The novel brain neuropeptide, orexin-A, modulates die sleep-wake cycle of rats. Eur. J. Neurosci. (2000) 12(2):726-730.
27. PEYRON C, FARACO J, ROGERS W et al.: A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat. Med. (2000) 6(9):991-997.
28. LIN L, FARACO J, LI H et al.: The sleep disorder canine narcolepsy is caused by mutation in the hypocretin (orexin) receptor 2 gene. Cell (1999) 98:365-376.
29. MIGNOT E, LIN L, ROGERS W et al.: Complex HLA-DR and -DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups. Am. J. Hum. Genet. (2001) 68:686-699.
30. MIGNOT E, THORSBY E: Narcolepsy and the HLA System. N. Engl. J. Med. (2001) 344(9):692.
31. YAMANAKA A, TSUJINO N, FUNAHASHI H et al.: Orexins activate histaminergic neurons via the orexin 2 receptor. Biochem. Biophys. Res. Commun. (2002) 290(4):1237-1245.
32. CHEMELLI RM, WILLIE JT, SINTON CM et al.: Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell (1999) 98:437-451.
33. BOURGIN P, HUITRON-RESENDIZ S, SPIER AD et al.: Hypocretin-1 modulates rapid eye movement sleep through activation of locuscoeruleus neurons. J. Neurosci. (2000) 20(20):7760-7765.
34. SMITH MI, PIPER DC, DUXON MS et al.: Evidence implicating a role for orexin-1 receptor modulation of paradoxical sleep in the rat. Neurosci. Lett. (2003) 341:256-258.
35. NISHINO S, RIPLEY B, OVEREEM S, NEVSIMALOVA S et al.: Low cerebrospinal fluid hypocretin (orexin) and altered energy homeostasis in human narcolepsy. Ann. Neurol. (2001) 50:381-388.
36. BINGHAM S, DAVEY PT, BABBS AJ et al.: Orexin-A: an hypothalamic peptide with analgesic properties. Pain (2001) 92:81-90.
37. HARRIS GC, WIMMER M, ASTON-JONES G: A role for lateral hypothalamic orexin neurons in reward seeking. Nature (2005) 437:556-559.
38. DILEONE RJ, GEORGESCU D, NESTLER EJ: Lateral hypothalamic neuropeptides in reward and drug addition. Life Sci. (2003) 73(6):759-768.
39. KELLEY AE, BALDO BA, PRATT WE: A proposed hypothalamic-thalamic-striatal axis for the integration of energy balance, arousal, and food reward. J. Comp. Neurol. (2005) 493(1):72-85.
40. KISANUKI Y, CHEMELLI RM, TOKITA S, WILLIE JT, SINTON CM, YANAGISAWA M: Behavioral and polysomnographic characterization of orexin-1 receptor and orexin-2 receptor double knockout mice. Sleep (2001) 24:A22.
41. 2R) knockout mice. Sleep (2001) 24:A20-A21.
42. WILLIE JT, SINTON CM, YANAGISAWA M, CHEMELLI RM: Narcoleptic behavioral arrests in orexin ligand and orexin-2 receptor knockout mice are neurophysiologically distinct. Sleep (2001) 24: A24.
43. YAMAMOTO T, NOZAKI-TAGUCHI N, CHIBA T: Analgesic effect of intrathecally administered orexin-A in the rat formalin test and in the rat hot plate test. Br. J. Pharmacol. (2002) 137(2):170-176.
44. SUYAMA H, KAWAMOTO S, SHIRAISHI S et al.: Analgesic effect of intrathecal administration of orexin on neuropathic pain in rats. In Vivo (2004) 18:119-123.
45. YAMAMOTO T, SAITO O, SHONO K et al.: Anti-mechanical allodynic effect of intrathecal and intracerebroventricular injection of orexin-A in the rat neuropathic pain model. Neurosci. Lett. (2003) 347:183-186.
46. KAJIYAMA S, KAWAMOTO M, SHIRAISHI S et al.: Spinal orexin-1 receptors mediate anti-hyperalgesic effects of intrathecally-administered orexins in diabetic neuropathic pain model rats. Brain Res. (2005) 1044:76-86.
47. CHENG JK, CHOU RCC, HWANG LL et al.: Antiallodynic effects of intrathecal orexins in a rat model of postoperative pain. J. Pharmacol. Exp. Ther. (2003) 307(3):1065-1071.
48. MOBARAKEH JI, TAKAHASHI K, SAKURADA S et al.: Enhanced antinociception by intracerebroventricularly and intrathecally-administered orexin A and B (hypocretin-1 and -2) in mice. Peptides (2005) 26:767-777.
49. 2 receptor gene knockout mice. Pain (2005) 118:254-262.
50. CHEN CT, HWANG LI, CHANG JK et al.: Pressor effects of orexins injected intracisternally and to rostral ventrolateral medulla of anesthetized rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2000) 278:R692-R697.
51. PU S, JAIN MR, KALRA PS et al.: Orexins, a novel family of hypothalamic neuropeptides, modulate pituitary luteinizing hormone secretion in an ovarian steroid-dependent manner. Regul. Pept. (1998) 78:133-136.
52. LUBKIN M, STRICKER-KRONGRAD A: Independent feeding and metabolic actions of orexins in mice. Biochem. Biophys. Res. Commun. (1998) 253:241-245.
53. TAKAHASHI N, OKUMURA T, YAMADA H et al.: Stimulation of gastric acid secretion by centrally administered orexin-A in conscious rats. Biochem. Biophys. Res. Commun. (1999) 254:623-627.
54. NAKAMURA T, URAMURA K, NAMBU T et al.: Orexin-induced hyperlocomotion and stereotypy are mediated by the dopaminergic system. Brain Res. (2000) 873:181-187.
55. WILLIE JT, CHEMELLI RM, SINTON CM et al.: To ear or to sleep? Orexin in the regulation of feeding and wakefulness. Ann. Rev. Neurosci. (2001) 24:429-458.
56. 3 reports: 622257, 627911.
57. PORTER RA, CHAN WN, COULTON S et al.: 1,3-Biarylureas as selective non-peptide antagonists of the orexin-1 receptor. Bioorg. Med. Chem. Lett. (2001) 11:1907-1910.
58. SMART D, SABIDO-DAVID C, BROUGH SJ: SB-334867-A: the first selective orexin-1 receptor antagonist. Br. J. Pharmacol. (2001) 132(6):1179-1182.
59. ISHII Y, BLUNDELL JE, RODGERS RJ et al.: Anorexia and weight loss in male rats 24 h following single dose treatment with orexin-1 receptor antagonist SB-334867. Behav. Brain Res. (2005) 157:331-341.
60. 1R antagonist on food intake and body weight in two strains of rats that differ in susceptibility to dietary-induced obesity. Peptides (2005) 26:2331-2338.
61. HAYNES AC, CHAMPMAN H, TAYLOR C et al.: Anorectic, thermogenic and anti-obesity activity of a selective orexin-1 receptor antagonist in ob/ ob mice. Regul. Pept. (2002) 104(1-3):153-159.
62. RODGERS RJ, HALFORD JC, NUNES DE SOUZA RL et al.: SB-334867, a selective orexin-1 receptor antagonist, enhances behavioural satiety and blocks the hyperphagic effect of orexin-A in rats. Eur. J. Neurosci. (2001) 17(7):1444-1452.
63. ISHII Y, BLUNDELL JE, HALFORD JC et al.: Differential effects of the selective orexin-1 receptor antagonist SB-334867 and lithium chloride on the behavioural satiety sequence in rats. Physiol. Behav. (2004) 81(1):129-140.
64. YAMADA H, TAKAHASHI N, OKUMURA T et al.: A selective orexin-1 receptor antagonist, SB334867, blocks 2-DG-induced gastric acid secretion in rats. Neurosci. Lett. (2005) 376:137-142.
65. EHRSTROM M, LEVIN F, KIRCHGESSNER AL et al.: Stimulatory effect of endogenous orexin A on gastric emptying and acid secretion independent of gastrin. Regul. Pept. (2005) 132:9-16.
66. HOLLAND PR, AKERMAN S, GOADSBY PJ: Orexin 1 receptor activation attenuates neurogenic dural vasodilation in an animal model of trigeminovascular nociception. J. Pharmacol. Exper. Ther. (2005) 315(3):1380-1385.
67. TAKAKUSAKI K, TAKAHASHI K, SAITOH K et al.: Orexinergic projections to the cat midbrain mediate alternation of emotional behavioural states from locomotion to cataplexy. J. Physiol. (2005) 568(3):1003-1020.
68. JONES DN, GARTLON J, PARKER F et al.: Effects of centrally administered orexin-B and orexin-A: a role for orexin-1 receptors in orexin-B induced hyperactivity. Psychopharmacology (2001) 153(2):210-218.
69. 2C receptor involvement. Psychopharmacology (2001) 153(2):203-209.
70. SOFFIN EM, EVANS ML, GILL CH et al.: SB-334867-A antagonises orexin mediated excitation in the locus coeruleus. Neuropharmacology (2002) 42(1):127-133.
71. 3H]-SB-674042, a novel nonpeptide antagonist, to the human orexin-1 receptor. Br. J. Pharmacol. (2004) 141(2):340-346.
72. KOBERSTEIN R, AISSAOUI H, BUR D et al.: Tetrahydroisoquinolines as orexin receptor antagonists: strategies for lead optimization by solution-phase chemistry. Chimia (2003) 57(5):270-275.
73. HIROSE M, EGASHIRA S-I, GOTO Y et al.: N-Acyl 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline: the first orexin-2 receptor selective non-peptide antagonist. Bioorg. Med. Chem. Lett. (2003) 13(1):4497-4499.
74. MCATEE LC, SUTTON SW, RUDOLPH DA et al.: Novel substituted 4-phenyl-[1,3]dioxanes: potent and selective orexin receptor 2 (OX2R) antagonists. Bioorg. Med. Chem. Lett. (2004) 14:4225-4229.